Melanotan 1
Afamelanotide
Melanotan 1 (Afamelanotide) is a hormonal & sexual research compound. MC1R-selective melanocortin agonist — drives melanin (tanning/photoprotection) more selectively than MT2.
Melanotan 1 quick facts
| Reported research dose (Injectable) | 250mcg-1000mcg |
| Route | Subq |
| Frequency | 1x Daily |
| Half-life | ~1-2 hrs |
| Forms | Injectable, Nasal |
| Evidence level | Approved (Scenesse, EPP); human |
| Other forms available | Nasal — dosed differently |
The 'cleaner' tan peptide — MC1R-selective, so fewer of MT2's side effects.
How Melanotan 1 works
MC1R-selective melanocortin agonist — drives melanin (tanning/photoprotection) more selectively than MT2.
Proposed benefits
Tanning and photoprotection via melanogenesis.
Where to get Melanotan 1
Melanotan 1 is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Melanotan 1
Graded by what exists behind each claim.
✅ Clinically validated
- Approved in Europe and the US as afamelanotide (Scenesse) for erythropoietic protoporphyria, on randomized trial data showing increased pain-free light exposure. That is a real approval for a real melanocortin analog.
- No trials for cosmetic tanning.
📊 Correlative data
- Used for tanning and photoprotection. Compared with Melanotan 2 the reported profile is markedly cleaner — little to no nausea, flushing or sexual effect — which is exactly what the selectivity predicts.
🧪 Theoretical / extrapolated
- A selective MC1R agonist — the melanocyte receptor — without meaningful MC3R/MC4R activity.
- That single difference from Melanotan 2 explains the entire difference in experience: MT2 is unselective and hits the appetite and libido receptors too. The shared MC1R action means the mole and skin-check caution applies to both, since stimulating melanocytes is the mechanism in each case.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Melanotan 1 actually does
This compound is an approved medicine, and almost nothing written about it in this market says so. Afamelanotide is the active ingredient of SCENESSE, approved by the FDA in 2019 to “increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)” U.S. Food and Drug Administration 2019. Melanotan-1 and afamelanotide are the same molecule. The tanning peptide sold in vials and the orphan drug delivered as a two-monthly subcutaneous implant are not analogs of each other — they are the same thirteen amino acids.
The chemistry, and two substitutions carry all of it. The label describes afamelanotide as “a synthetic tridecapeptide and a structural analog of alpha-melanocyte stimulating hormone (α-MSH)” that is “a melanocortin receptor agonist and binds predominantly to MC1-R” U.S. Food and Drug Administration 2019. Its research name spells out the modifications: [Nle⁴-D-Phe⁷]-α-MSH Dorr 2000. Position 4 is norleucine instead of methionine — methionine's thioether oxidizes and inactivates the native hormone, and norleucine is the same shape without the sulfur. Position 7 is D-phenylalanine instead of L — which both blocks proteolysis at that bond and locks the pharmacophore into a conformation the receptor holds more tightly. Native α-MSH lasts minutes and is a modest agonist. Two changes make it superpotent and durable.
MC1-R selectivity is the whole difference from its sibling. There are five melanocortin receptors. MC1-R is on the melanocyte and governs pigment; MC3-R and MC4-R sit in the hypothalamus and govern appetite and sexual arousal; MC5-R is on exocrine glands. The label says afamelanotide binds predominantly to MC1-R U.S. Food and Drug Administration 2019. That single word is why this peptide produces tanning without the spontaneous erections, nausea and flushing that make its less selective relative notorious — and it is the most practically useful fact on this page.
What it does inside the melanocyte, and the read-out is specific. The label states it “increases production of eumelanin in the skin independently of exposure to sunlight” U.S. Food and Drug Administration 2019. MC1-R is a G-protein-coupled receptor; agonism raises cAMP, which drives MITF and shifts melanogenesis from the pheomelanin branch to the eumelanin branch. Those two pigments are not interchangeable: eumelanin is the brown-black, photoprotective, free-radical-quenching one; pheomelanin is the red-yellow one that generates reactive oxygen species under UV rather than absorbing it.
And that branch shift has been measured in human skin, by biopsy. Dorr 2000 gave seven volunteers ten daily subcutaneous doses over two weeks and analyzed shave biopsies by HPLC. One week after treatment ended, eumelanin — measured as its permanganate oxidation product PTCA — had risen 49% ± 17.6% in forehead skin (P = 0.019) and 98% ± 25.4% in forearm skin (P = 0.003), while pheomelanin did not significantly change. The eumelanin-to-pheomelanin ratio in forearm skin went from 51:1 to 86:1. That is the mechanism visible in a chromatogram: not more pigment generally, but selectively more of the protective pigment.
Cell, rodent, human — and where it stops
Step one, human pharmacokinetics and tanning, in three people. Ugwu 1997 compared intravenous, oral and subcutaneous melanotan-I in three male volunteers, ten doses over two weeks, with plasma levels by radioimmunoassay and tanning by serial reflectometry. Three results matter and they have never been superseded: subcutaneous dosing was completely bioavailable relative to intravenous; no drug was detectable at all after oral dosing; and tanning of forehead, arms and neck peaked one week after the last dose and was still present three weeks after the course finished.
Step two, the pigment chemistry. Dorr 2000, described above: seven volunteers, 0.16 mg/kg/day subcutaneously, Monday to Friday over two weeks, with biopsy-proven selective eumelanin increase. Hold that dose — it is the number this page turns on.
Step three, two randomized placebo-controlled trials with a hard clinical endpoint, published in the New England Journal of Medicine. Langendonk 2015 ran a European trial in 74 patients and a United States trial in 94 patients with erythropoietic protoporphyria, randomized 1:1 to subcutaneous implants containing 16 mg of afamelanotide or placebo every 60 days — five implants over 180 days in Europe, three over 270 days in the US. The primary efficacy endpoint was the number of hours of direct exposure to sunlight without pain. In the US study, median pain-free time at 6 months was 69.4 hours versus 40.8 on placebo (P = 0.04). In the European study at 9 months it was 6.0 hours versus 0.8 (P = 0.005), with 77 phototoxic reactions versus 146 (P = 0.04). Quality of life improved in both.
Step four, eight years of real-world use. Biolcati 2015 followed 115 EPP patients given 1,023 implants over up to eight years at porphyria centers in Rome and Zurich. By June 2014, 66% of all EPP patients known to those centers were on it. Quality-of-life scores rose from 31 ± 24% of maximum to 74% and stayed there. Only three patients felt it had not met their expectations; 23% discontinued for other reasons such as pregnancy or cost. Adverse events were minor and predominantly nausea.
The obstacle, and it is a change of both indication and product. Every controlled number above was generated in people with an inherited photosensitivity disease, using a 16 mg controlled-release implant inserted above the anterior supra-iliac crest by a healthcare professional trained by the manufacturer, at a maximum of six implants per year U.S. Food and Drug Administration 2019. The endpoint was hours of sunlight without pain. Nobody has run a controlled trial of afamelanotide for cosmetic tanning at any dose by any route. The two human tanning studies that exist Ugwu 1997 Dorr 2000 enrolled three and seven people, in 1997 and 2000, using a daily subcutaneous injection that no approved product has ever used.
And the dose gap runs the opposite way to most of this catalog. Dorr 2000 used 0.16 mg/kg/day — in an 80 kg adult, 12.8 mg per day, ten times over two weeks. This site's card lists 250 to 1,000 µg per dose. The dose that produced biopsy-measured eumelanin increases was therefore roughly 13 to 50 times larger than the community dose. That does not mean the community dose does nothing — pigment is a visible, self-reporting endpoint and the anecdotal record is not ambiguous — it means the only human dose with a chemical measurement behind it is not the dose being used.
Melanotan 1 pharmacokinetics — how much of it actually gets in
Two different half-lives are correct for this molecule, and they belong to two different products. This site's card says about 1–2 hours. The FDA label says about 15 hours U.S. Food and Drug Administration 2019. Both are right and the difference is formulation, not disagreement.
The injected peptide. Ugwu 1997 measured, after subcutaneous bolus dosing, an absorption-phase half-life of 0.07 to 0.79 hours and a beta-phase half-life of 0.8 to 1.7 hours, with clearance of 0.12 to 0.19 L/kg/h and 3.9% or less of the dose recovered in urine. That is the card's number and it is the right one for a vial.
The implant. The label reports Cmax 3.7 ± 1.3 ng/mL, median Tmax 36 hours, AUC(0-inf) 138.9 ± 42.6 h·ng/mL and a half-life of approximately 15 hours U.S. Food and Drug Administration 2019. A Tmax of 36 hours for a peptide with a sub-two-hour intrinsic half-life can only mean one thing: the terminal phase being measured is the dissolution of the implant, not the elimination of the peptide. The implant converts a molecule that disappears in an afternoon into one that is delivered over days, which is exactly why a single insertion covers 60 days of photoprotection.
Oral is not a route for this molecule, and that is measured rather than assumed. Ugwu 1997 dosed 0.16 mg/kg by mouth and reported no detectable drug levels. A thirteen-residue peptide meets gastric acid and pancreatic proteases and does not arrive. Anything sold as an oral melanotan is either a different substance or nothing.
What degrades it. The label is unusually candid: afamelanotide “may undergo hydrolysis. However, its metabolic profile has not been fully characterized” U.S. Food and Drug Administration 2019. No cytochrome, no named peptidase, and less than 4% of a subcutaneous dose in urine Ugwu 1997 — so the peptide is being taken apart into amino acids and recycled rather than excreted intact. That is the ordinary fate of a small peptide and it is the reason there is no drug-interaction section worth writing.
The pharmacodynamic lag is the number to plan around, not the half-life. Melanogenesis takes days: the receptor signal has to raise MITF, build melanosomes and transfer them to keratinocytes, and the keratinocytes then have to migrate outward. Ugwu 1997 found tanning peaking one week after the last of ten doses and still present at three weeks. So the drug is gone from plasma in hours and the effect arrives a week later and persists for weeks — which means dosing decisions made on how you look today are being made on information a week out of date.
What would have to be true, and how you would know it was not
Four predictions with a marker, a direction and a window. The fourth is the one that cuts against the compound and it is the reason the approved product carries a monitoring requirement.
1. Visible pigmentation should appear on a one-to-three-week clock, not a two-day one. Ugwu 1997 measured tanning peaking one week after the tenth dose and persisting at three weeks. The falsification is straightforward: photograph the inner forearm under identical light at baseline, day 7, day 14 and day 21. Nothing at day 21 in a person with functional melanocytes means the material is not working, and no amount of additional dosing before then is informed.
2. Sun-exposed sites should darken more than covered ones, and the face and neck should lead. Dorr 2000 found tanning at three of eight anatomic sites — face, neck and forearm — and measured nearly twice the eumelanin increase in forearm skin (98%) as in forehead skin (49%), on skin types III and IV. If a response appears uniformly everywhere including covered skin, that is a different pattern from the published one.
3. No standard blood marker should move. There is no hematological, hepatic, renal or endocrine parameter reported to shift on afamelanotide in the label's controlled data U.S. Food and Drug Administration 2019. For an MC1-R-selective agonist that is the expected result — the receptor is on melanocytes. Anyone who orders a panel to monitor this peptide will find nothing, and knowing that in advance is worth more than the panel.
4. The prediction that cuts against it: your existing moles will get darker, and that is a surveillance problem rather than a cosmetic one. The label's Warnings section says it directly: SCENESSE “may lead to generalized increased skin pigmentation and darkening of pre-existing nevi and ephelides because of its pharmacologic effect”, and requires that “a full body skin examination (twice yearly) is recommended to monitor pre-existing and new skin pigmentary lesions” U.S. Food and Drug Administration 2019. In the controlled data, melanocytic nevus was reported in 4% on afamelanotide versus 2% on vehicle, and skin hyperpigmentation in 4% versus 0%. The read-out here is not a blood test — it is a dermatologist, twice a year, with your baseline photographs. The mechanism darkens the exact lesions that melanoma screening depends on being able to see change in.
What nobody has tested yet
Nobody has ever run a controlled trial of this peptide for tanning. The two human tanning studies enrolled three Ugwu 1997 and seven Dorr 2000 volunteers, twenty-six and twenty-nine years ago. Every controlled trial since has been in EPP with a pain endpoint. A randomized study in healthy volunteers with reflectometry, biopsy eumelanin and a dermatologist-scored mole count would be straightforward, and the entire cosmetic use of an approved drug rests on ten people from the 1990s.
Nobody has established whether the eumelanin increase actually protects DNA. The mechanistic case is strong — eumelanin absorbs UV and quenches radicals, and Dorr 2000 showed the ratio shifting from 51:1 to 86:1 — but the experiment that matters is different: minimal erythema dose, cyclobutane pyrimidine dimer formation, or p53 induction in biopsied skin before and after treatment. In EPP the endpoint was pain, not DNA. Whether a melanotan-induced tan is photoprotective in the way a UV-induced tan is, or merely looks like one, has not been measured.
Nobody has run the melanoma question that the label implies. Langan 2009 reported a change in moles linked to use of an unlicensed sun-tan injection, and the label mandates twice-yearly full body skin examination U.S. Food and Drug Administration 2019. What does not exist is a cohort: several hundred users, dermoscopic imaging at baseline and annually, with excision rates and histology. Biolcati 2015 followed 115 patients for up to eight years with 1,023 implants and reported only minor adverse events — a genuinely reassuring dataset, and one assembled in a disease population under specialist supervision rather than in unsupervised cosmetic users.
Nobody has compared the implant with injections head to head. A 16 mg implant delivering over 60 days and a 250–1000 µg injection given every few days produce completely different concentration-time profiles from the same molecule U.S. Food and Drug Administration 2019 Ugwu 1997. Whether continuous low exposure and pulsatile higher exposure produce the same pigment response — or the same nevus darkening — is unknown, and the answer would matter to every person choosing between them.
Melanotan 1 — its own safety story, not its class's
The single most important safety fact on this page is a monitoring requirement, not an adverse effect. The label's Warnings and Precautions section requires a full body skin examination twice yearly to monitor pre-existing and new skin pigmentary lesions, because the drug darkens pre-existing nevi and ephelides as a pharmacologic effect U.S. Food and Drug Administration 2019. This is not a theoretical worry. Melanoma is detected by noticing that a mole has changed. A drug whose mechanism changes every mole simultaneously removes the signal that detection depends on, and the FDA responded by writing a surveillance schedule into the label of an orphan drug for a disease with a few thousand patients worldwide.
The controlled adverse-event table, with its denominators. Over six months, afamelanotide (n = 125) versus vehicle (n = 119) U.S. Food and Drug Administration 2019: implant site reaction 21% versus 10%, nausea 19% versus 14%, oropharyngeal pain 7% versus 5%, cough 6% versus 3%, fatigue 6% versus 3%, skin hyperpigmentation 4% versus 0%, dizziness 4% versus 3%, melanocytic nevus 4% versus 2%, respiratory tract infection 4% versus 3%, somnolence 2% versus 1%. Nausea is the standout and it matches Biolcati 2015, where nausea was the predominant adverse event across 1,023 implants.
Two of those rows deserve pulling out. Skin hyperpigmentation at 4% versus 0% is the drug doing its job, reported as an adverse event because it was unwanted. Melanocytic nevus at 4% versus 2% is the numeric version of the monitoring warning — a doubling on a small base, in a six-month trial. Neither is dangerous by itself; together they are the reason for the dermatologist.
The published harm signal from the unlicensed market. Langan 2009 is a report in the BMJ of change in moles linked to use of an unlicensed ‘sun tan jab’. That is exactly the product this page is about — not the implant, not the trial, the vial — and it is the case literature the approved label's monitoring requirement is consistent with.
The delivery difference is itself a safety difference. The approved product is inserted by a healthcare professional proficient in subcutaneous implantation who has completed manufacturer training, at a maximum of six implants per year, above the anterior supra-iliac crest U.S. Food and Drug Administration 2019. Nothing in the reconstituted vial route has a ceiling, a trained inserter, or a two-monthly cadence. The person choosing their own dose is choosing an exposure with no upper bound written anywhere — and the label's own annual limit is the closest thing to guidance that exists.
What this compound does not do, said plainly because its reputation is borrowed from a relative. The flushing, nausea spikes, spontaneous erections and appetite suppression that dominate community discussion of ‘melanotan’ belong to the non-selective melanocortin agonist. This molecule binds predominantly MC1-R U.S. Food and Drug Administration 2019, and the label's own trial data — nausea 19% versus 14% on vehicle, and nothing sexual on the table at all — reflects that. Confusing the two is the most common error made about this peptide, in both directions.
Sources read for this page
- U.S. Food and Drug Administration. SCENESSE (afamelanotide) implant, for subcutaneous use - full prescribing information (NDA 210797).. FDA approved labeling, revision 2019
- Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. Afamelanotide for Erythropoietic Protoporphyria.. N Engl J Med 2015 · PMID 26132941
- Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.. Br J Dermatol 2015 · PMID 25494545
- Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME, Aickin M, Hruby VJ. Skin pigmentation and pharmacokinetics of melanotan-I in humans.. Biopharm Drug Dispos 1997 · PMID 9113347
- Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, Alberts DS. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.. Photochem Photobiol 2000 · PMID 11045725
- Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed sun tan jab.. BMJ 2009 · PMID 19174439
Melanotan 1 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are melanocortin receptor agonists and they are not selective, which is the whole safety story. MC1R gives the tanning. MC4R gives the nausea, the flushing and the erections. You do not get to choose which receptors respond.
- The mole question is the one that matters. These drive melanogenesis systemically — existing naevi commonly darken and new ones can appear. That is not itself cancer, but it makes melanoma surveillance harder precisely in people using a tanning agent.
What has actually been reported
- Nausea in the first hours after dosing is very common and usually settles with repeated exposure. Facial flushing, spontaneous erections and appetite suppression are all frequently reported.
- Case reports exist of melanoma diagnosed in Melanotan users. Causation is not established and the population self-selects for sun exposure — but 'unproven' is not 'reassuring' here.
How to reduce the risk
Same mechanism as the prediction.
- Get a full-body skin check before you start, and photograph your moles. This is the whole mitigation. The predicted problem is that melanogenesis makes surveillance harder — a dated set of baseline photographs is what makes 'has this changed?' answerable later.
- Start at a fraction of the intended dose. The nausea and flushing are MC4R effects that attenuate with exposure, so almost everyone who has a miserable first experience simply started too high.
- Dose in the evening. If the nausea lands, you sleep through the worst of it.
- Sun protection does not become optional because you tan faster. Melanin is partial protection, and the tan is not the part that matters here — the mole surveillance is.
- Any new lesion, or an existing one that changes shape, color or border, is a dermatologist appointment rather than a forum question.
What it does to your bloodwork
A fact about the assay.
- No routine marker tracks this. The monitoring here is dermatological, not hematological — get a skin check and photograph your moles before you start.
Don't run this if
- Personal or family history of melanoma, or many atypical moles.
- Any pigmented lesion you have not had looked at.
The honest unknown
- Whether driving melanogenesis for years changes melanoma risk in humans. Nobody has run that study and it is not obvious anyone will.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Melanotan 1 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Melanotan 1 moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Blood pressure is the thing to watch here and it is not a lab — melanocortin agonists can raise it transiently after dosing.
What to do: Take blood pressure before and an hour after a dose the first few times. That tells you more than any panel.
The mechanism-predicted concern that matters is not on a blood panel: melanocortin agonists stimulate melanocytes, so existing moles darkening or changing is the signal to take seriously, and a skin check before starting is the version of a baseline that applies here.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Melanotan 1 in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Melanotan 1
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | General baseline — but bloodwork is not the monitoring that matters here |
Check results you already have → · All 103 markers A–Z
Melanotan 1 — frequently asked questions
What is Melanotan 1?
Melanotan 1 (Afamelanotide) is a hormonal & sexual research compound. MC1R-selective melanocortin agonist — drives melanin (tanning/photoprotection) more selectively than MT2.
Is the full Melanotan 1 protocol on this page?
The reported research dose is on this page, along with how Melanotan 1 works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Melanotan 1?
Melanotan 1 has an approximate half-life of ~1-2 hrs, which is part of what determines how often it's dosed.
What forms does Melanotan 1 come in?
Melanotan 1 is available as: Injectable, Nasal.
What's the evidence behind Melanotan 1?
Current evidence level: Approved (Scenesse, EPP); human. Melanotan 1 is offered for research purposes only and is not an approved medicine.
Melanotan 1 inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Melanotan 1 is used for
Melanotan 1 appears under 1 goal in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
Melanotan 1 is the photoprotection arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.